Address
304 North Cardinal
St. Dorchester Center, MA 02124
Work Hours
Monday to Friday: 7AM - 7PM
Weekend: 10AM - 5PM
CJC-1295 comes in two versions that work completely differently — and confusing them changes what you're actually researching. This guide covers the real DAC versus no-DAC distinction, the 2006 human trial that doesn't match current use, a named FDA safety signal, and the practical dosing math for this widely-used compound.
Semaglutide, tirzepatide, and retatrutide all target the same goal through one, two, or three receptor pathways — but potency and evidence maturity move in opposite directions. This guide compares real head-to-head trial data, cardiovascular outcomes, and safety profiles side by side, so you can see exactly where each compound actually stands.
TB-500 isn't thymosin beta-4 — it's a small fragment of it, and the real human trial history actually belongs to a completely different formulation and route. This guide covers that critical distinction, the actual FDA regulatory status, and everything needed to research this compound alongside its constant companion, BPC-157.
BPC-157 has one of the most extensive preclinical evidence bases in this guide series — and one of the thinnest human ones. This guide covers a real 2005 human trial that was never published, the current FDA and WADA status, and the practical math for dosing this widely-researched compound.
Semaglutide brought GLP-1 research into the mainstream, but nearly a decade of data exists behind the headlines. This guide covers the real approval timeline, what the evidence actually shows, how it stacks up against tirzepatide and retatrutide, and everything needed to run a first protocol safely and confidently.
Tesamorelin stands apart from every other GH-axis compound in this guide series — it's the only one with genuine FDA approval and a completed Phase 3 program behind it. This guide covers its real clinical evidence, the documented HbA1c safety signal, and how it compares to CJC-1295 and Ipamorelin's far thinner trial history.
IGF-1 LR3 works downstream of GH secretagogues like CJC-1295 — activating the same receptor those compounds aim to boost signal to. This guide covers its real mechanism, why it needs acetic acid instead of standard BAC water, a genuine blood sugar risk with a concrete action plan, and why no human trial supports its actual use case.
GHK-Cu has the strongest human clinical evidence of any regenerative compound in this series — but almost entirely for topical use, not the injectable route most researchers actually want. This guide covers that critical distinction, the genuine 50-year research history, and the visible quality check no other compound offers.
NAD+ IV therapy is available at thousands of clinics worldwide — and a 2025 systematic review found zero completed outcomes trials for injectable use, for any of the claims it's marketed on. This guide covers what's actually been shown, the real mechanism behind the flush, and how it compares to oral precursors.
Melanotan II's non-selective mechanism produces pigmentation, appetite suppression, and libido effects from one injection — which is both its appeal and its risk. This guide covers the real receptor pharmacology, verified safety considerations including priapism and melanoma risk, and corrects fabricated statistics circulating widely elsewhere about this compound.
